SCHEMBL244547

SCHEMBL244547

O=C(c1ccc2c(c1)OCO2)N1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
CYP2C9 P11712 1/20 1.00
CYP2C19 P33261 1/20 1.00
ALDH1A1 P00352 6/20 0.97
HSD17B10 Q99714 2/20 0.88
TSHR P16473 4/20 0.82
RECQL P46063 2/20 0.82
MAPT P10636 2/20 0.71
NPC1 O15118 1/20 0.71
PKM P14618 1/20 0.71
RAB9A P51151 1/20 0.71
MAOB P27338 2/20 0.69
GAA P10253 1/20 0.66
GFER P55789 1/20 0.66
LMNA P02545 1/20 0.63
KMT2A Q03164 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13486221 1.00 HPGD (1.00) HPGDCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL14140751 1.00 HPGD (1.00) HPGDCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5970063 0.98 HPGD (1.00) HPGDCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL108225 0.92 ALDH1A1 (0.90) HPGDCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL244490 0.90 HPGD (1.00) HPGDCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7464300 0.84 HPGD (0.75) HPGDCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7433458 0.84 HPGD (0.75) HPGDCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL8475795 0.83 HPGD (0.71) HPGDCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL93930 0.83 ALDH1A1 (0.76) HPGDCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL23675311 0.83 HPGD (0.69) HPGDCYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115721652-B Application of Securinega suffruticosa alkali or derivative thereof 赣南医学院 2024-03-08 CN claimed
CN-114178612-B Novel board sawing machine 浙江锯力煌工业科技股份有限公司 2023-09-08 CN claimed
CN-114540534-B Moso bamboo oligonucleotide probe 浙江农林大学 2023-08-25 CN claimed
CN-114540348-B Moso bamboo oligonucleotide probe 浙江农林大学 2023-06-30 CN claimed
CN-115721652-A Application of securinine or derivatives thereof 赣南医学院 2023-03-03 CN claimed
US-20230010108-A1 A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-01-12 US claimed
CN-114540348-A Phyllostachys pubescens oligonucleotide probe 浙江农林大学 2022-05-27 CN claimed
CN-114540534-A Mao bamboo oligonucleotide probe 浙江农林大学 2022-05-27 CN claimed
CN-112980833-B Phyllostachys pubescens oligonucleotide probe and obtaining method and using method thereof 浙江农林大学 2022-05-06 CN claimed
US-20160257957-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-09-08 US claimed
US-20130058915-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS Children's Medica Center Corporation (US) 2013-03-07 US claimed
EP-2544688-A2 METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS President and Fellows of Harvard College (US) 2013-01-16 EP claimed
WO-2011109398-A2 METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-09-09 WO claimed
WO-2006034196-A1 COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR LIFELIKE BIOMATIC INC. (US) 2006-03-30 WO claimed
US-20060063707-A1 Compositions for enhancing memory and methods therefor LIFELIKE BIOMATIC, INC. (US) 2006-03-23 US claimed
US-20250388685-A1 METHODS FOR TREATING CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST SANOFI BIOTECHNOLOGY (FR) 2025-12-25 US disclosed
EP-4638436-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-10-29 EP disclosed
WO-1997034878-A1 SUBSTITUTED 2,3-BENZODIAZEPIN-4-ONES AND THE USE THEREOF COCENSYS, INC. (US) 1997-09-25 WO disclosed
EP-0651746-A1 DRUGS THAT ENHANCE SYNAPTIC RESPONSES MEDIATED BY AMPA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1995-05-10 EP disclosed
WO-1994002475-A1 DRUGS THAT ENHANCE SYNAPTIC RESPONSES MEDIATED BY AMPA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1994-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063707-A1 Compositions for enhancing memory and methods therefor GRIN1, GRIN3A, GRIN2A HPGD 1202/4885CYP1A2 4871/4885CYP3A4 4785/4885
US-20230010108-A1 A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP DAO, DDO, DCLRE1A HPGD 877/4885CYP1A2 1441/4885CYP3A4 2182/4885
US-20250388685-A1 METHODS FOR TREATING CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST IL4, CCR4, IL1RN HPGD 1358/4885CYP1A2 796/4885CYP3A4 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.